Gender (Females N (%)) |
16 (94.1) |
Age at disease onset (years, M, (IQR) |
31(23-42.5) |
Age at SF sampling (years, M, (IQR) |
57 (48.5-63.2) |
Disease duration (years, M, (IQR) |
16 (6-34) |
Active smoking at sampling (N (%)) |
6 (35.3) |
Organ involvement |
|
Lupus Nephritis (N (%)) |
3 (17.6) |
Cutaneous manifestations (N (%)) |
6 (35.3) |
Neurolupus (N (%)) |
3 (17.6) |
Serositis (N (%)) |
2 (11.8) |
Secondary APS (N (%)) |
3 (17.6) |
Treatment at sampling |
|
Glucocorticoids (N (%)) |
10 (58.8) |
Antimalarial (N (%)) |
10 (58.8) |
Methotrexate (N (%)) |
3 (17.6) |
Combined therapy# (N (%)) |
6 (35.3) |
No active treatment (N (%)) |
2 (11.8) |
Autoantibodies |
|
ANA (N (%)) |
17 (100) |
anti-dsDNA (N (%)) |
6 (35.3) |
RF (N (%)) |
2 (11.8) |
anti-SSA/SSB (N (%)) |
4 (23.5) |
anti-RNP (N (%)) |
3 (17.6) |
anti-PL (N (%)) |
9 (52.9) |